Oruka Therapeutics
ORKA
106 hedge funds and large institutions have $876M invested in Oruka Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 8 closing their positions.
869% more capital inflows, than outflows
Capital inflows: $187M | Capital outflows: $19.3M
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
29% more funds holding
Funds holding: 82 → 106 (+24)
2.15% more ownership
Funds ownership: 91.96% → 94.11% (+2.2%)
84% less call options, than puts
Call options by funds: $497K | Put options by funds: $3.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$39.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.3M |
| 3 |
Avoro Capital Advisors
New York
|
+$19.8M |
| 4 |
Perceptive Advisors
New York
|
+$18.8M |
| 5 |
Deep Track Capital
Greenwich,
Connecticut
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.54M |
| 2 |
Braidwell
Stamford,
Connecticut
|
-$2.11M |
| 3 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.85M |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
-$1.81M |
| 5 |
Cable Car Capital
San Francisco,
California
|
-$1.48M |
ORKA Hedge Fund Activity: Q3 2025 in Review
106 of the 7,658 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2025, worth a combined $876M — up 127% from $386M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ORKA positions and 8 closed out — a net gain of 24 holders — while 31 added to existing stakes and 22 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $39.5M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $6.54M sold.
- 106 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2025, up from 82 in Q2 2025.
- Funds reported $876M of Oruka Therapeutics stock for Q3 2025, up 127% quarter-over-quarter.
- 32 funds opened new Oruka Therapeutics positions in Q3 2025 and 8 closed out, a net change of +24 holders.
- The largest Oruka Therapeutics buyer in Q3 2025 was Viking Global Investors, an estimated $39.5M added.
- The largest Oruka Therapeutics seller in Q3 2025 was Frazier Life Sciences Management, an estimated $6.54M sold.
Based on aggregated 13F filings for Q3 2025.